Robert Wallin
Chief Scientific Officer & Founder SeqCure Immunology
I have been interested in, and worked with cancer immunotherapy ever since I read: The Transformed cell by Steven Rosenberg in 1993. I got my PhD in Immunology from Karolinska Institutet 2003, made a post doc in at the Wellcome Trust Biocentre, University of Dundee 2004 – 2006 and then worked as an assistant/associate professor at Karolinska Institutet 2006-2012. 2013 I took a position as Vice President Education, Indonesia International Institute for Life Sciences, i3L, participating in the foundation of this new institute. 2014 I founded a life science consulting company, SciEd Solutions and 2017 I went back to my original interest, tumor immunology, realizing that the technologies were now mature to accomplish truly effective individualized cancer T-cell therapy and thus founded SeqCure Immunology to pursue this.
Seminars
- Which patient populations and disease settings offer the greatest opportunity to demonstrate the value of personalized cancer vaccines in clinical development?
- How should developers balance efficacy, durability, toxicity, and operational complexity when designing combination regimens?
- What manufacturing innovations and regulatory strategies are needed to consistently deliver individualized therapies at scale?
- We have developed SeqCureNEO to make a T-cell therapy with full control over specificity, potency and therapeutic dose
- Currently cancer vaccines have only shown promise in the setting of minimal residual disease and vaccine responses are commonly only seen to a few of the neoantigen epitopes
- We propose combining SeqCureNEO with a cancer vaccine based on the same neoepitopes. Why such a combination would create more potent clinical responses will be discussed in the talk
